Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravulizumab for HSCT-associated thrombotic microangiopathy
CTR20233577Phase 3Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ravulizumab in transplant-associated thrombotic microangiopathy (TA-TMA), sponsored by Alexion Pharmaceuticals. Started Jan 2024; status: completed.
02
Drugs
ravulizumab
03
Conditions
transplant-associated thrombotic microangiopathy (TA-TMA)
Beyond the preview
Go deeper on CTR20233577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233577.